Results 91 to 100 of about 1,870 (108)

Targeted and Armed Oncolytic Poxviruses for Cancer: the Lead Example of JX-594

Current Pharmaceutical Biotechnology, 2012
Oncolytic viruses (OVs) are designed to replicate in, and subsequently lyse cancer cells. Numerous oncolytic virus platforms are currently in development. Here we review preclinical and clinical experience with JX-594, the lead candidate from the targeted and armed oncolytic poxvirus class. JX-594 is derived from a vaccinia vaccine strain that has been
Caroline J, Breitbach, Steve H, Thorne, John C, Bell, David H, Kirn   +3 more
openaire   +2 more sources

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

The Lancet Oncology, 2008
JX-594 is a targeted oncolytic poxvirus designed to selectively replicate in and destroy cancer cells with cell-cycle abnormalities and epidermal growth factor receptor (EGFR)-ras pathway activation. Direct oncolysis plus granulocyte-macrophage colony-stimulating factor (GM-CSF) expression also stimulates shutdown of tumour vasculature and antitumoral ...
Park, B.H., Hwang, T., Liu, T.C., Sze, D.Y., Kim, J.S., Kwon, H.C., Oh, S.Y., Han, S.Y., Yoon, J., Hong, S., Moon, A., Speth, K., Park, C., Ahn, Y.J., Daneshmand, M., Rhee, B.G., Pinedo, H.M., Bell, J., Kirn, D.H.   +18 more
openaire   +4 more sources

Clinical proof-of-concept with JX-594, a novel targeted multi-mechanistic oncolytic poxvirus, in patients with refractory liver tumors

Journal of Clinical Oncology, 2008
3573 Background: JX-594 is a first-in-class targeted oncolytic poxvirus designed to selectively replicate in and destroy cancer cells with cell cycle abnormalities and EGFR/ ras pathway activation....
T. Liu, B. Park, T. Hwang, H. Kwon, S. Oh, S. Han, A. Moon, K. Speth, H. M. Pinedo, J. Bell, D. H. Kirn   +10 more
openaire   +1 more source

Imaging approaches to assess mechanism-of-action and response in patients with advanced hepatocellular carcinoma treated with the novel oncolytic poxvirus JX-594.

Journal of Clinical Oncology, 2013
210 Background: The novel oncolytic virus JX-595 has demonstrated anti-cancer mechanisms of action, as defined in preclinical models, which includes cytolysis, intra-tumoral vascular disruption, and immune-mediated tumor targeting. Methods: To determine whether mechanism(s) of action (MOA) of the novel anti-cancer oncolytic virus JX-594 could be ...
Richard H. Patt, David H. Kirn, Caroline Breitbach, James M. Burke, Riccardo Lencioni   +4 more
openaire   +1 more source

A phase II trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology, 2012
e14566 Background: JX-594 is a targeted oncolytic vaccinia virus designed to selectively replicate in and destroy cancer cells with epidermal growth factor receptor (EGFR)/ ras pathway activation. Direct oncolysis plus GM-CSF expression is accompanied by tumor vascular disruption and anti-tumoral immunity (Reviewed in Nat Rev Cancer 2009). JX-594 was
Jeong Heo, Caroline Breitbach, Mong Cho, Tae-Ho Hwang, Chang Won Kim, Ung Bae Jeon, Hyun Young Woo, Ki Tae Yoon, Jun Woo Lee, James Burke, Theresa Hickman, Kara S DuBois, Lara Longpre, Richard H. Patt, David H. Kirn   +14 more
openaire   +1 more source

JX-594, a targeted oncolytic poxvirus for the treatment of cancer.

Current opinion in investigational drugs (London, England : 2000), 2010
JX-594 is a replication-competent Wyeth strain vaccinia virus that was genetically modified to inactive the endogenous thymidine kinase gene and to express human GM-CSF and LacZ genes. In development by Jennerex Inc and licensee Green Cross Corp, the modified virus is a novel therapy for treatment-refractive metastatic malignancies from various sites ...
Alison E, Merrick, Elizabeth J, Ilett, Alan A, Melcher   +2 more
openaire   +1 more source

Evaluating antivascular effects and antitumoral activity in patients with hepatocellular carcinoma treated with JX-594, a targeted multimechanistic oncolytic poxvirus, prior to sorafenib therapy.

Journal of Clinical Oncology, 2010
e14564 Background: JX-594 is a first-in-class targeted oncolytic poxvirus designed to selectively replicate in and destroy cancer cells with epidermal growth factor receptor (EGFR)/ ras pathway activation. Direct oncolysis plus granulocyte macrophage, colony stimulating factor (GM-CSF) expression stimulates acute tumor vascular shutdown and antitumoral
J. Heo, D. H. Kirn, C. Breitbach, M. Cho, R. Patt, C. Kim, S. Kim, B. Rhee, J. C. Bell, T. Hwang   +9 more
openaire   +1 more source

A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma

2015
Primary liver cancer (hepatocellular carcinoma; HCC) in patients not eligible for surgery or transplant is currently treated by locoregional therapeutic approaches, including trans-arterial chemoembolization and radiofrequency ablation. Sorafenib (Nexavar; Bayer/Onyx) is currently the only approved systemic therapy for patients having failed ...
Caroline J, Breitbach, Anne, Moon, James, Burke, Tae-Ho, Hwang, David H, Kirn   +4 more
openaire   +2 more sources

Abstract 2841: Widespread endothelial cell infection and tumor cell apoptosis after intravenous injection of oncolytic vaccinia virus JX-594 into RIP-Tag2 mice.

Cancer Research, 2013
Abstract Replication-competent oncolytic viruses are being developed as a promising strategy for treating certain types of cancer. JX-594 is an oncolytic vaccinia virus that lacks thymidine kinase and expresses human granulocyte-macrophage colony stimulating factor (hGM-CSF).
Barbara Sennino, Brian J. Schriver, Caroline J. Breitbach, Naomi De Silva, John C. Bell, David H. Kirn, Donald M. McDonald   +6 more
openaire   +1 more source

Abstract PS3-13-06: Antitumor activity of the oncolytic virus JX-594 in patient-derived xenograft models of triple-negative breast cancer

Clinical Cancer Research
Abstract Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This profile limits treatment options primarily to chemotherapy, which is
J. Lee, Y. Kim, Y. Cha, N. Lee, K. Oh, J. Jeong, J. Kim   +6 more
openaire   +1 more source